[go: up one dir, main page]

Min et al., 2023 - Google Patents

Lactobacillus plantarum NCU1125 mitigates intestinal barrier injury induced by cyclophosphamide in mice

Min et al., 2023

Document ID
5136527870999066176
Author
Min F
Hu J
Zhong Y
Huang T
Huang Y
Nie S
Xiong T
Xie M
Publication year
Publication venue
Food Bioscience

External Links

Snippet

A previous study demonstrated that Lactobacillus (L.) plantarum NCU1125, derived from fermented Nanfeng mandarin, survived in vitro simulated gastrointestinal digestion, suggesting potential probiotic properties. The current study aimed to investigate the efficacy …
Continue reading at www.sciencedirect.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Micro-organisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor

Similar Documents

Publication Publication Date Title
Xie et al. Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice
Yu et al. Lactobacillus plantarum L15 alleviates colitis by inhibiting LPS-mediated NF-κB activation and ameliorates DSS-induced gut microbiota dysbiosis
Lim et al. Bifidobacterium adolescentis IM38 ameliorates high-fat diet–induced colitis in mice by inhibiting NF-κB activation and lipopolysaccharide production by gut microbiota
Chang et al. Ganoderma lucidum reduces obesity in mice by modulating the composition of the gut microbiota
Diling et al. Extracts from Hericium erinaceus relieve inflammatory bowel disease by regulating immunity and gut microbiota
Ferrere et al. Fecal microbiota manipulation prevents dysbiosis and alcohol-induced liver injury in mice
Wan et al. Modulation of gut microbiota by Ilex kudingcha improves dextran sulfate sodium-induced colitis
Wang et al. Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease
Zhu et al. Bifidobacteria attenuate the development of metabolic disorders, with inter-and intra-species differences
Min et al. Lactobacillus plantarum NCU1125 mitigates intestinal barrier injury induced by cyclophosphamide in mice
Jin et al. β-Glucan-triggered Akkermansia muciniphila expansion facilitates the expulsion of intestinal helminth via TLR2 in mice
Kemgang et al. Fermented milk with probiotic Lactobacillus rhamnosus S1K3 (MTCC5957) protects mice from salmonella by enhancing immune and nonimmune protection mechanisms at intestinal mucosal level
Zhu et al. Probiotic cocktail alleviates intestinal inflammation through improving gut microbiota and metabolites in colitis mice
Štofilová et al. Cytokine production in vitro and in rat model of colitis in response to Lactobacillus plantarum LS/07
Kim et al. Lactic acid bacteria improves Peyer's patch cell-mediated immunoglobulin A and tight-junction expression in a destructed gut microbial environment
Dong et al. Immunomodulatory effects of mixed Lactobacillus plantarum on lipopolysaccharide-induced intestinal injury in mice
Wang et al. Lactobacillus fermentum CECT5716 alleviates the inflammatory response in asthma by regulating TLR2/TLR4 expression
Wang et al. Polysaccharides from fermented coix seed modulates circulating nitrogen and immune function by altering gut microbiota
Li et al. Parabacteroides goldsteinii enriched by Pericarpium Citri Reticulatae ‘Chachiensis’ polysaccharides improves colitis via the inhibition of lipopolysaccharide-involved PI3K-Akt signaling pathway
Xu et al. Effects of Rosa roxburghii & edible fungus fermentation broth on immune response and gut microbiota in immunosuppressed mice
Li et al. Exopolysaccharides and Surface-Layer proteins expressed by Biofilm-State Lactiplantibacillus plantarum Y42 play crucial role in preventing intestinal barrier and immunity dysfunction of Balb/C mice infected by Listeria monocytogenes ATCC 19115
Yao et al. Effect of Paecilomyces cicadae polysaccharide Pc0-1 on cyclophosphamide-induced immunosuppression and regulation of intestinal flora in mice
Lee et al. Paraprobiotic derived from Bacillus velezensis GV1 improves immune response and gut microbiota composition in cyclophosphamide-treated immunosuppressed mice
Xu et al. Immune-enhancing efficacy of Curtobacterium proimmune K3 lysates isolated from Panax ginseng beverages in cyclophosphamide-induced immunosuppressed mice
Zhu et al. Lacticaseibacillus rhamnosus LRa05 alleviates cyclophosphamide‐induced immunosuppression and intestinal microbiota disorder in mice